Short-term trials show GLP-1 agonists preserve grip strength despite lean mass loss, but longer-term data in older adults with diabetes suggest possible acceleration of muscle strength decline and sarcopenia risk.
Lean mass ≠ strength predictionLean tissue loss from GLP-1 drugs does not reliably predict actual muscle strength changes — strength can be preserved (short-term) or decline (long-term) independently of mass changes
What the researchers found
The review identifies a divergence between short-term and long-term findings:
Short-to-mid-term trials (semaglutide, liraglutide in obesity):
- Handgrip strength was statistically preserved despite reductions in lean soft tissue mass
- Tirzepatide combined with resistance and aerobic training did not add strength benefits beyond exercise alone in young men
Longer-term data (older adults with type 2 diabetes):
- Longitudinal and retrospective studies reported reductions in handgrip strength with prolonged semaglutide use
- Accelerated sarcopenia was observed
- Potential detrimental effects on neuromuscular health
Key insight: lean soft tissue loss is NOT a reliable predictor of muscle strength change following GLP-1/GIP agonist use — strength can be preserved despite mass loss (short-term) or decline despite what appears to be proportional mass loss (long-term).
Why it matters
Sarcopenia (age-related muscle loss) is already a major health problem in older adults, increasing the risk of falls, fractures, disability, and death. If GLP-1 drugs accelerate muscle strength decline in this population, the weight loss benefits could be offset by increased frailty. This is particularly concerning because older adults with type 2 diabetes — a primary target population for these drugs — are already at elevated sarcopenia risk. The review calls for monitoring muscle strength, not just weight and lean mass, in patients on these medications.
How the study worked
This is a narrative review summarizing emerging evidence from short-to-mid-term clinical trials, longitudinal studies, and retrospective research on GLP-1/GIP receptor agonists and muscle strength outcomes. The review compares findings across different drug types (semaglutide, liraglutide, tirzepatide), populations (younger adults with obesity vs. older adults with diabetes), and study durations.
What this study cannot tell us
As a narrative review, this does not present original data or systematic methodology. The longer-term concerning findings come from retrospective and observational studies, which are prone to confounding. The definition and measurement of sarcopenia varies across studies. Handgrip strength is only one measure of muscle function and may not capture all relevant neuromuscular changes. The review does not distinguish between different GLP-1 drugs, doses, or treatment durations in detail. The role of concurrent exercise and nutrition is not consistently controlled across the cited studies.
How to read the evidence
This is a narrative review synthesizing evidence from clinical trials (short-term) and observational studies (long-term). The short-term trial evidence is relatively strong (RCTs), while the concerning long-term findings come from weaker observational designs. The overall evidence for GLP-1 effects on muscle strength is emerging and inconclusive.
When this study was published
Published in 2026, this review addresses a rapidly evolving safety question as GLP-1 agonist prescribing continues to expand in older populations.
The bigger picture
This review addresses one of the most important safety questions in the GLP-1 revolution. As these drugs expand from diabetes to obesity, cardiovascular protection, kidney disease, and potentially Alzheimer's, the population taking them — including many older adults — is growing rapidly. The disconnect between lean mass and strength challenges the commonly used body composition endpoints in clinical trials. If muscle strength outcomes had been primary endpoints instead of lean mass changes, the clinical picture might look very different. This could reshape how future GLP-1 trials are designed.
Questions still open
- Should muscle strength testing be a mandatory monitoring requirement for older adults prescribed GLP-1 agonists long-term?
- Would combining GLP-1 therapy with resistance training and protein supplementation prevent the long-term strength decline seen in older adults?
- Is the neuromuscular effect specific to GLP-1 agonists, or does it occur with any rapid weight loss in older populations?
Common questions
Why might GLP-1 drugs affect muscle strength differently in younger versus older adults?
Should older people stop taking GLP-1 drugs because of muscle concerns?
Read the original research
Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions.
British journal of pharmacology
Citation
Prokopidis, Konstantinos. (2026). Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions.. British journal of pharmacology. https://doi.org/10.1111/bph.70355